Guidance for Industry on Drug Substance Chemistry, Manufacturing, and Controls Information; Availability, 47604-47605 [2010-19360]
Download as PDF
47604
Federal Register / Vol. 75, No. 151 / Friday, August 6, 2010 / Notices
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the agency’s current thinking
on therapeutic drug assays that measure
lamotrigine or zonisamide. It does not
create or confer any rights for or on any
person and does not operate to bind
FDA or the public. An alternative
approach may be used if such approach
satisfies the requirements of the
applicable statute and regulations.
III. Electronic Access
IV. Paperwork Reduction Act of 1995
This draft guidance refers to
previously approved collections of
information found in FDA regulations.
These collections of information are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). The collections
of information in 21 CFR part 807,
subpart E, have been approved under
OMB control number 0910–0120; the
collections of information in 21 CFR
809.10 have been approved under OMB
control number 0910–0485.
sroberts on DSKD5P82C1PROD with NOTICES
V. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES), either electronic or written
comments regarding this document. It is
only necessary to send one set of
comments. It is no longer necessary to
send two copies of mailed comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
16:35 Aug 05, 2010
[FR Doc. 2010–19419 Filed 8–5–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Persons interested in obtaining a copy
of the draft guidance may do so by using
the Internet. To receive
‘‘Recommendations for Premarket
Notifications for Lamotrigine and
Zonisamide Assays,’’ you may either
send an e-mail request to
dsmica@fda.hhs.gov to receive an
electronic copy of the document or send
a fax request to 301–847–8149 to receive
a hard copy. Please use the document
number 1654 to identify the guidance
you are requesting. A search capability
for all CDRH guidance documents is
available at https://www.fda.gov/
MedicalDevices/DeviceRegulationand
Guidance/GuidanceDocuments/
default.htm. Guidance documents are
also available at https://
www.regulations.gov.
VerDate Mar<15>2010
Dated: August 2, 2010.
Nancy Stade,
Acting Associate Director for Regulations and
Policy, Center for Devices and Radiological
Health.
Jkt 220001
Draft Guidance for Industry and Food
and Drug Administration Staff; Medical
Devices; Neurological and Physical
Medicine Device Guidance Document;
Reopening of Comment Period;
Correction
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug
Administration (FDA) is correcting a
notice that appeared in the Federal
Register of July 28, 2010 (75 FR 44267).
The document reopened the comment
period for a notice of availability of draft
guidance documents for 11 neurological
and physical medicine devices. The
document was published with an
inadvertent error. This document
corrects that error.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Joyce Strong, Office of Policy, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, rm. 3208,
Silver Spring, MD 20993, 301–796–
9148.
In FR Doc.
2010–18406, appearing on page 44267,
in the Federal Register of Wednesday,
July 28, 2010, the following correction
is made:
1. On page 44267, in the first column,
the heading ‘‘[Docket No. FDA–2009–N–
0495]’’ is corrected to read ‘‘[Docket No.
FDA–2009–D–0495]’’.
SUPPLEMENTARY INFORMATION:
Dated: July 30, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–19355 Filed 8–5–10; 8:45 am]
BILLING CODE 4160–01–S
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
Food and Drug Administration
[Docket No. FDA–2003–D–0243] (formerly
2003D–0571)
Guidance for Industry on Drug
Substance Chemistry, Manufacturing,
and Controls Information; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a guidance for industry
#169 entitled ‘‘Drug Substance
Chemistry, Manufacturing, and Controls
Information.’’ This guidance provides
recommendations on the chemistry,
manufacturing, and controls (CMC)
information for drug substances that
should be submitted to support original
new animal drug applications (NADAs)
and abbreviated new animal drug
applications (ANADAs). The guidance
is structured to facilitate the preparation
of applications submitted in Common
Technical Document (CTD) format.
DATES: Submit either electronic or
written comments on agency guidances
at any time.
ADDRESSES: Submit written requests for
single copies of the guidance to the
Communications Staff (HFV–12), Center
for Veterinary Medicine, Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855. Send one selfaddressed adhesive label to assist that
office in processing your requests. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the guidance
document.
Submit electronic comments to https://
www.regulations.gov. Submit written
comments on the guidance to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
FOR FURTHER INFORMATION CONTACT:
Alem Ghiorghis, Center for Veterinary
Medicine (HFV–143), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240–276–8266,
email: alem.ghiorghis@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
[Docket No. FDA–2009–D–0495]
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
I. Background
In the Federal Register of June 1, 2006
(71 FR 31194), FDA published the
notice of withdrawal and revision of
seven guidances. CVM made Level II
revisions to draft guidance entitled
‘‘Drug Substance Chemistry,
Manufacturing, and Controls
E:\FR\FM\06AUN1.SGM
06AUN1
Federal Register / Vol. 75, No. 151 / Friday, August 6, 2010 / Notices
Information’’ to support their continued
use in CVM for the approval of new
animal drugs (e.g., removed references
to human drug and biological products).
The guidance announced in this notice
finalizes the draft guidance dated June
1, 2006.
This level 1 guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the agency’s
current thinking on the topic. It does not
create or confer any rights for or on any
person and does not operate to bind
FDA or the public. An alternative
approach may be used if such approach
satisfies the requirements of the
applicable statutes and regulations.
III. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
section 512 of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 360b) have
been approved under OMB Control No.
0910–0032.
IV. Comments
sroberts on DSKD5P82C1PROD with NOTICES
Submit written requests for single
copies of the guidance to the
Communications Staff (HFV–12), Center
for Veterinary Medicine, Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855. Send one selfaddressed adhesive label to assist that
office in processing your requests.
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) either electronic or written
comments regarding this document. It is
only necessary to send one set of
comments. It is no longer necessary to
send two copies of mailed comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
V. Electronic Access
Persons with access to the Internet
may obtain the guidance at either https://
www.fda.gov/AnimalVeterinary/
GuidanceComplianceEnforcement/
GuidanceforIndustry/default.htm or
https://www.regulations.gov.
16:35 Aug 05, 2010
[FR Doc. 2010–19360 Filed 8–5–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
II. Significance of Guidance
VerDate Mar<15>2010
Dated: July 30, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
Jkt 220001
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Vaccines and Related Biological
Products Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: Vaccines and
Related Biological Products Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on September 21, 2010, from 2
p.m. to approximately 6 p.m.
Location: National Institutes of Health
(NIH), Building 29B/Conference Room
C. The public is welcome to attend the
meeting at the specified location where
a speakerphone will be provided. Public
participation in the meeting is limited to
the use of the speakerphone in the
conference room. Important information
about transportation and directions to
the NIH campus, parking, and security
procedures is available on the Internet
at https://www.nih.gov/about/visitor/
index.htm. (FDA has verified the Web
site address, but FDA is not responsible
for any subsequent changes to the Web
site after this document publishes in the
Federal Register.) Visitors must show
two forms of identification, one of
which must be a government-issued
photo identification such as a Federal
employee badge, driver’s license,
passport, green card, etc. Detailed
information about security procedures is
located at https://www.nih.gov/about/
visitorsecurity.htm. Due to the limited
available parking, visitors are
encouraged to use public transportation.
Contact Person: Christine Walsh or
Denise Royster, Center for Biologics
Evaluation and Research (HFM–71),
Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852,
301–827–0314, or FDA Advisory
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
47605
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), code
3014512391. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On September 21, 2010, the
committee will meet in open session to
hear updates of the research programs in
the Laboratory of Respiratory & Special
Pathogens, Division of Bacterial,
Parasitic, & Allergenic Products;
Laboratory of Hepatitis Viruses, and
Laboratory of Vector Borne Virus
Diseases, Division of Viral Products,
Office of Vaccines Research and Review,
Center for Biologics Evaluation and
Research, FDA.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: On September 21, 2010,
from 2 p.m. to approximately 5:10 p.m.,
the meeting is open to the public.
Interested persons may present data,
information, or views, orally or in
writing, on issues pending before the
committee. Written submissions may be
made to the contact person on or before
September 15, 2010. Oral presentations
from the public will be scheduled
between approximately 4:10 p.m. and
5:10 p.m. Those desiring to make formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before September 9, 2010. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
E:\FR\FM\06AUN1.SGM
06AUN1
Agencies
[Federal Register Volume 75, Number 151 (Friday, August 6, 2010)]
[Notices]
[Pages 47604-47605]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-19360]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2003-D-0243] (formerly 2003D-0571)
Guidance for Industry on Drug Substance Chemistry, Manufacturing,
and Controls Information; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a guidance for industry 169 entitled ``Drug
Substance Chemistry, Manufacturing, and Controls Information.'' This
guidance provides recommendations on the chemistry, manufacturing, and
controls (CMC) information for drug substances that should be submitted
to support original new animal drug applications (NADAs) and
abbreviated new animal drug applications (ANADAs). The guidance is
structured to facilitate the preparation of applications submitted in
Common Technical Document (CTD) format.
DATES: Submit either electronic or written comments on agency
guidances at any time.
ADDRESSES: Submit written requests for single copies of the guidance
to the Communications Staff (HFV-12), Center for Veterinary Medicine,
Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855.
Send one self-addressed adhesive label to assist that office in
processing your requests. See the SUPPLEMENTARY INFORMATION section for
electronic access to the guidance document.
Submit electronic comments to https://www.regulations.gov. Submit
written comments on the guidance to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Alem Ghiorghis, Center for Veterinary
Medicine (HFV-143), Food and Drug Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240-276-8266, email: alem.ghiorghis@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of June 1, 2006 (71 FR 31194), FDA
published the notice of withdrawal and revision of seven guidances. CVM
made Level II revisions to draft guidance entitled ``Drug Substance
Chemistry, Manufacturing, and Controls
[[Page 47605]]
Information'' to support their continued use in CVM for the approval of
new animal drugs (e.g., removed references to human drug and biological
products). The guidance announced in this notice finalizes the draft
guidance dated June 1, 2006.
II. Significance of Guidance
This level 1 guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The guidance represents
the agency's current thinking on the topic. It does not create or
confer any rights for or on any person and does not operate to bind FDA
or the public. An alternative approach may be used if such approach
satisfies the requirements of the applicable statutes and regulations.
III. Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in section 512 of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 360b) have been approved under OMB Control
No. 0910-0032.
IV. Comments
Submit written requests for single copies of the guidance to the
Communications Staff (HFV-12), Center for Veterinary Medicine, Food and
Drug Administration, 7519 Standish Pl., Rockville, MD 20855. Send one
self-addressed adhesive label to assist that office in processing your
requests.
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) either electronic or written comments regarding this
document. It is only necessary to send one set of comments. It is no
longer necessary to send two copies of mailed comments. Identify
comments with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
V. Electronic Access
Persons with access to the Internet may obtain the guidance at
either https://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm or https://www.regulations.gov.
Dated: July 30, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-19360 Filed 8-5-10; 8:45 am]
BILLING CODE 4160-01-S